T-VEC

talimogene laherparepvec · Amgen

Drug timelines are a Plus or Pro feature.

9 regulatory and trial events tracked for T-VEC, covering 2020-06-17 to 2025-10-29. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma [Phase 2]

See pricing